Detalhe da pesquisa
1.
Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
Lancet
; 389(10069): 612-620, 2017 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28069279
2.
Telangiectasia macularis eruptiva perstans (TMEP): A form of cutaneous mastocytosis with potential systemic involvement.
J Am Acad Dermatol
; 74(5): 885-91.e1, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26899198
3.
Midostaurin in Advanced Systemic Mastocytosis.
N Engl J Med
; 374(26): 2605-7, 2016 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27355555
4.
In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells.
Blood
; 120(24): 4846-9, 2012 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-23074272
5.
SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes.
Haematologica
; 99(5): 830-5, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24389310
6.
Blood CD34-c-Kit+ cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor.
Blood
; 118(19): 5246-9, 2011 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-21878676
7.
Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations.
Blood
; 116(7): 1114-23, 2010 Aug 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-20484085
8.
Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Eur J Haematol
; 89(1): 47-52, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22324351
9.
Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors.
Mol Cancer Res
; 6(7): 1137-45, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-18644978
10.
Adult T cell leukemia aggressivenness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression.
Oncotarget
; 8(32): 52256-52268, 2017 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28881727
11.
Prevalence and risk factors for fragility fracture in systemic mastocytosis.
Bone
; 105: 219-225, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28919366
12.
Mastocytosis among elderly patients: A multicenter retrospective French study on 53 patients.
Medicine (Baltimore)
; 95(24): e3901, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27310990
13.
Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors.
PLoS One
; 10(11): e0142450, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26562302
14.
ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
PLoS One
; 9(1): e85362, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24465546
15.
Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive.
Case Rep Hematol
; 2012: 517546, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22997594
16.
Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.
PLoS One
; 5(3): e9430, 2010 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-20209107
17.
Case-control cohort study of patients' perceptions of disability in mastocytosis.
PLoS One
; 3(5): e2266, 2008 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-18509466
18.
Phenotypic and genotypic characteristics of mastocytosis according to the age of onset.
PLoS One
; 3(4): e1906, 2008 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-18404201